background
previous
show
small
interf
rna
sirna
target
zair
ebola
viru
zebov
rna
polymeras
l
protein
formul
stabl
nucleic
acidlipid
particl
snalp
complet
protect
guineapig
administ
shortli
lethal
zebov
challeng
although
rodent
model
zebov
infect
use
screen
prospect
countermeasur
frequent
use
predict
effi
caci
stringent
nonhuman
primat
model
therefor
assess
effi
caci
modifi
ed
nonimmunostimulatori
sirna
uniformli
lethal
nonhuman
primat
model
zebov
haemorrhag
fever
find
two
three
rhesu
monkey
given
four
postexposur
treatment
pool
antizebov
sirna
protect
lethal
zebov
infect
wherea
macaqu
given
seven
postexposur
treatment
protect
treatment
regimen
second
studi
well
toler
minor
chang
liver
enzym
might
relat
viral
infect
interpret
complet
postexposur
protect
zebov
nonhuman
primat
provid
model
treatment
zebovinduc
haemorrhag
fever
data
show
potenti
rna
interfer
eff
ectiv
postexposur
treatment
strategi
peopl
infect
ebola
viru
suggest
strategi
might
also
use
treatment
emerg
viral
infect
fund
defens
threat
reduct
agenc
year
ebola
viru
ebov
associ
period
episod
haemorrhag
fever
central
africa
produc
sever
diseas
infect
patient
mortal
rate
outbreak
rang
sudan
speci
ebov
sebov
zair
speci
zebov
outbreak
toward
end
caus
appar
new
speci
ebov
uganda
seem
less
pathogen
sebov
zebov
case
fatal
rate
ebov
particl
contain
noninfecti
rna
genom
roughli
kilobas
encod
seven
structur
protein
one
nonstructur
protein
gene
order
leader
nucleoprotein
virion
protein
vp
glycoprotein
polymeras
l
protein
trailer
four
proteinsnucleoprotein
polymeras
l
proteinar
associ
viral
genom
rna
ribonucleoprotein
complex
l
protein
make
polymeras
complex
transcrib
replic
ebov
genom
l
protein
provid
rnadepend
rna
polymeras
activ
complex
protein
ideal
target
antivir
intervent
suppress
lead
nearli
complet
loss
rna
synthesi
also
absenc
similar
protein
mammalian
cell
also
promis
target
antivir
intervent
sinc
shown
inhibitori
eff
ect
host
type
interferon
respons
specifi
calli
function
type
interferon
antagonist
block
activ
interferon
regulatori
factor
possibl
prevent
transcript
interferon
consist
fi
nding
mutat
zebov
render
adapt
viru
avirul
guineapig
express
interfer
type
interferon
signal
mutat
link
adapt
zebov
produc
lethal
infect
mice
guineapig
although
vaccin
postexposur
treatment
prevent
manag
ebov
infect
progress
made
past
year
develop
candid
prevent
vaccin
protect
nonhuman
primat
infect
ebov
progress
develop
antivir
drug
basic
local
align
search
tool
see
http
jurawi
mitedubiocsirnaext
postexposur
intervent
much
slower
rna
interfer
repres
promis
intervent
treatment
diseas
includ
caus
virus
inde
rna
interfer
use
cell
cultur
system
rodent
inhibit
replic
sever
pathogen
caus
diseas
human
be
howev
use
eff
ectiv
treatment
nonhuman
primat
model
human
infecti
diseas
assess
two
studi
small
interf
rna
sirna
inhibit
replic
hepat
gb
viru
b
nonleth
marmoset
surrog
model
human
hepat
c
sirna
sever
acut
respiratori
syndrom
sar
coronaviru
inhibit
viru
replic
nonleth
rhesu
monkey
model
howev
unmodifi
ed
immun
stimulatori
sirna
use
studi
potenti
confound
interpret
result
use
rna
interfer
postexposur
treatment
assess
lethal
model
human
infecti
diseas
nonhuman
primat
previou
studi
identifi
ed
sirna
target
zebov
polymeras
l
protein
inhibit
replic
zebov
vitro
complet
protect
zebovinfect
guineapig
although
eff
ectiv
chose
use
cocktail
three
sirna
present
studi
one
zebov
l
protein
gene
studi
nonhuman
primat
premis
combin
sirna
aid
target
potenti
rnainterfer
escap
mutant
shown
polio
virus
target
three
diff
erent
viral
gene
product
also
aim
inactiv
viru
three
diff
erent
stage
life
cycl
design
sirna
target
region
zebov
mayinga
strain
polymeras
l
gene
use
convent
sirna
design
algorithm
exclud
sirna
sequenc
homolog
human
refer
mrna
contigu
base
within
core
duplex
use
basic
local
align
search
tool
version
sirna
duplex
synthesis
dharmacon
chicago
il
usa
integr
dna
technolog
bvba
leuven
belgium
previous
describ
sirna
target
gene
identifi
ed
screen
vitro
reduct
express
zebov
zebov
viral
transgen
insert
dualluciferas
plasmid
system
promega
madison
wi
usa
control
promot
cell
lipofectamin
invitrogen
life
technolog
carlsbad
ca
usa
complex
contain
plasmid
sirna
nonspecifi
c
neg
control
sirna
nmoll
nmoll
nmoll
nmoll
nmoll
nmoll
nonspecifi
c
neg
control
sirna
nmoll
nmoll
nmoll
ad
plate
addit
cell
cell
per
well
cell
lyse
h
transfect
dualluciferas
report
assay
system
promega
berthold
luminomet
berthold
detect
system
pforzheim
germani
use
measur
renilla
luciferas
fuse
zebov
zebov
transgen
fi
refl
luciferas
signal
renilla
luciferas
signal
normalis
fi
refl
luciferas
signal
express
percentag
gene
express
rel
plasmidonli
control
assign
valu
tabl
show
sequenc
sirna
use
assess
whether
mrna
polymeras
l
cleav
specifi
c
mechan
rna
interfer
plate
vero
cell
cell
per
ml
ml
per
well
sixwel
plate
h
treat
stabl
nucleic
acidlipid
particl
snalp
nmoll
contain
sirna
modifi
ed
substitut
version
guanin
uridin
zebov
cocktail
consist
ratio
luciferas
sirna
luc
mod
h
infect
zebov
kikwit
strain
multipl
infect
h
infect
cell
supernat
harvest
quantit
realtim
rtpcr
cell
monolay
lyse
trizol
invitrogen
isol
total
rna
rapid
amplifi
cation
cdna
end
invitrogen
purifi
ed
viral
rna
use
qiagen
qiamp
viral
rna
mini
kit
qiagen
valencia
ca
usa
accord
manufactur
protocol
onestep
quantit
realtim
rtpcr
reaction
done
lightcycl
roch
indianapoli
usa
volum
purifi
ed
rna
superscript
iii
onestep
rtpcr
system
invitrogen
primer
forward
revers
taqman
probe
groov
binder
nonfl
uoresc
appli
biosystem
foster
citi
ca
usa
specifi
c
zebov
glycoprotein
gene
cycl
condit
revers
transcript
min
initi
denatur
min
follow
cycl
denatur
anneal
synthesi
singl
acquisit
fi
nal
cool
absolut
quantifi
cation
viral
gene
express
base
viral
rna
standard
use
softwar
version
rna
extract
race
done
describ
except
use
genespecifi
c
primer
gsp
cdna
product
gsp
predict
size
race
pcr
product
base
pair
base
pair
sampl
process
two
separ
transfect
similar
result
peripher
blood
mononuclear
cell
pbmc
isol
whole
blood
healthi
donor
use
standard
ficollhypaqu
densiti
centrifug
techniqu
immun
stimul
assay
done
previous
describ
nativ
unmodifi
ed
ed
sirna
nmoll
nmoll
nmoll
cultur
pbmc
h
lower
limit
quantifi
cation
interferon
pgml
mean
sd
calcul
three
separ
cultur
well
one
repres
experi
human
cord
blood
stem
cell
stem
cell
technolog
vancouv
bc
canada
cultur
day
iscov
modifi
ed
dulbecco
medium
glutamax
invitrogen
serum
substitut
stem
cell
technolog
human
ldl
calbiochem
san
diego
ca
usa
mercaptoethanol
human
peptid
deformylaserel
tyrosin
ligand
ngml
human
stemcel
factor
ngml
human
thrombopoietin
ngml
four
peprotech
rocki
hill
nj
usa
cell
media
replac
everi
day
prime
cell
diff
erenti
posit
supplement
recombin
human
interleukin
ngml
ngml
r
system
minneapoli
mn
usa
day
day
cell
diff
erenti
mix
myeloid
dendrit
cell
macrophag
cultur
addit
recombin
human
macrophag
colonystimul
factor
ngml
recombin
human
granulocytemacrophag
colonystimul
factor
ngml
peprotech
cultur
diff
erenti
cell
incub
snalp
contain
fl
uorescein
isothiocyan
fitc
nmoll
label
luc
mod
h
harvest
wash
fetal
bovin
serum
phosphatebuff
ere
salin
pb
stain
fl
uorescentlabel
antibodi
bd
bioscienc
san
jose
ca
usa
cell
phenotyp
marker
cell
uptak
snalp
contain
fitclabel
luc
mod
separ
accord
phenotyp
analys
threelas
eightcolour
lsrii
fl
ow
cytomet
facsdiva
softwar
version
mous
studi
complet
accord
canadian
council
anim
care
guidelin
follow
approv
local
anim
care
use
committe
tekmira
pharmaceut
anim
research
done
complianc
anim
welfar
act
feder
statut
regul
relat
anim
experi
involv
anim
adher
principl
state
guid
care
use
laboratori
anim
nation
research
council
facil
use
fulli
accredit
associ
assess
accredit
laboratori
anim
care
intern
femal
icr
mice
immunostimul
studi
four
mice
per
group
male
femal
mice
toler
zebov
target
sequenc
analysi
concentr
cytokin
plasma
interferoninduc
protein
tetra
tricopeptid
repeat
mrna
upregul
mrna
tissu
sensit
measur
localis
interferon
product
plasma
interferon
protein
elisa
assay
liver
done
previous
report
lower
limit
quantifi
cation
interferon
interleukin
elisa
pgml
initi
assess
toler
anim
inject
snalp
uninfect
mice
mgkg
per
day
mgkg
per
day
mgkg
per
day
day
euthanis
h
fi
nal
dose
cumul
dose
mgkg
mgkg
mgkg
equal
exceed
expect
dose
intens
nonhuman
primat
effi
caci
model
blood
serum
analys
clinic
chemistri
activ
alanin
aminotransferas
aspart
aminotransferas
sorbitol
dehydrogenas
complet
blood
count
done
clinic
sign
organ
weight
monitor
studi
sirna
encapsul
snalp
process
spontan
vesicl
format
report
jeff
colleagu
cation
ndimethylamino
propan
result
snalp
dialys
pb
fi
lter
sterilis
fi
lter
use
particl
size
batch
nm
eg
averag
size
snalp
contain
zebov
snalp
use
nonhuman
primat
studi
nm
low
polydispers
valu
indic
particl
homo
geneiti
aggreg
typic
sirna
encapsul
within
lipid
particl
amount
endotoxin
less
eumg
sirna
batch
investig
protect
effi
caci
lead
antizebov
sirna
establish
rhesu
macaqu
model
zebovinduc
haemorrhag
fever
nine
healthi
fi
lovirusseroneg
chines
rhesu
macaqu
macaca
mulatta
kg
use
nonhuman
primat
studi
hickman
leonard
broviac
central
venou
cathet
bard
access
system
salt
lake
citi
ut
insert
macaqu
previous
describ
monkey
place
primat
jacket
lomir
biomed
malon
ny
usa
return
cage
tether
continu
intraven
infus
salin
mlh
provid
anim
entir
studi
basic
singl
syring
infus
pump
kd
scientifi
c
holliston
usa
day
anim
inocul
intramuscularli
target
dose
plaqueform
unit
pfu
zebov
kikwit
strain
actual
dose
pfu
studi
pfu
studi
fi
rst
studi
pool
antizebov
sirna
formul
snalp
mgkg
total
sirna
per
dose
bolu
intraven
infus
administ
three
four
macaqu
min
zebov
challeng
control
anim
given
treatment
three
treat
anim
given
addit
treatment
snalpformul
antizebov
sirna
dose
day
zebov
challeng
control
anim
given
treatment
second
studi
investig
whether
creas
frequenc
treatment
could
improv
outcom
pool
snalpformul
antizebov
sirna
mgkg
per
dose
bolu
intraven
infus
administ
four
fi
macaqu
min
zebov
challeng
control
anim
given
equal
dose
snalpformul
nonspecifi
c
modifi
ed
sirna
luc
mod
min
zebov
challeng
anim
given
addit
treatment
snalp
formul
antizebov
sirna
snalpformul
nonspecifi
c
sirna
control
day
zebov
challeng
anim
given
physic
examin
blood
collect
tube
contain
edta
time
challeng
day
fi
loviru
challeng
nonhuman
primat
studi
use
laserbas
haematolog
analys
coulter
electron
hialeah
fl
usa
obtain
total
white
blood
cell
count
white
blood
cell
diff
erenti
red
blood
cell
count
platelet
count
haematocrit
valu
total
haemoglobin
mean
cell
volum
mean
corpuscular
volum
mean
corpuscular
haemoglobin
concentr
use
piccolo
pointofcar
blood
analys
abaxi
sunnyval
ca
usa
measur
concentr
albumin
amylas
alanin
aminotransferas
aspart
aminotransferas
alkalin
phosphatas
glutamyltransferas
glucos
cholesterol
total
protein
total
bilirubin
blood
urea
nitrogen
creatinin
serum
sampl
viru
titrat
use
convent
plaqu
assay
vero
cell
cell
cultur
fl
uid
blood
sampl
collect
rhesu
monkey
previous
describ
sponsor
provid
fi
nancial
support
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
author
access
primari
data
take
respons
accuraci
complet
data
report
fi
nal
respons
decis
submit
public
effi
caciou
sirna
silenc
zebov
gene
cell
effi
caciou
silenc
zebov
gene
fi
gure
sequenc
select
sirna
zebov
snalp
cocktail
sinc
nonselect
chemic
modifi
cation
might
attenu
potenc
sirna
select
modifi
ed
lead
sirna
substitut
guanosin
uridin
strand
elimin
immun
stimulatori
capac
sirna
duplex
confi
rmed
gene
silenc
activ
modifi
ed
version
use
invitro
plasmidbas
zebov
gene
express
system
data
shown
snalp
contain
modifi
ed
zebov
sirna
induc
interferon
interleukin
plasma
mice
wherea
snalp
contain
chemic
unmodifi
ed
luc
sirna
induc
high
concentr
plasma
cytokin
fi
gure
b
analysi
liver
mrna
show
diff
erenc
snalp
contain
pb
neg
control
contain
ed
luc
zebov
sirna
cocktail
wherea
snalp
contain
unmodifi
ed
luc
induc
high
level
mrna
greater
pb
control
fi
gure
diff
erenc
note
clinic
sign
organ
weight
mice
treat
snalp
contain
sirna
pb
nativ
chemic
unmodifi
ed
version
luc
sirna
also
induc
high
level
interferon
cultur
human
pbmc
wherea
ed
version
sirna
nmoll
induc
interferon
fi
gure
figur
show
snalp
contain
zebov
sirna
substanti
reduc
zebov
produc
supernat
vero
cell
h
infect
figur
show
snalp
contain
induc
specifi
c
mrna
cleavag
target
mrna
cell
wherea
three
pcr
product
correct
predict
size
present
cell
treat
snalp
contain
zebov
cocktail
sirna
fi
gure
pcr
product
predict
size
note
cell
treat
snalp
contain
pb
luc
mod
fi
gure
show
specifi
citi
assay
sequenc
pcr
product
data
shown
correspond
specifi
c
cleavag
product
polymeras
l
protein
mrna
therebi
confi
rming
specifi
c
mechan
rna
interfer
show
antizebov
sirna
target
popul
cell
relev
fi
loviru
infect
assess
uptak
snalp
liver
mice
human
myeloid
cell
cultur
snalp
enabl
entri
sirna
cell
reticuloendotheli
system
shown
uptak
fl
uoresc
snalp
kupff
er
cell
murin
liver
data
shown
subset
human
myeloid
cell
posit
fi
gure
data
show
snalp
activ
taken
reticuloendotheli
cell
popul
relev
ebov
infect
toler
studi
activ
alanin
aminotransferas
aspart
amino
transferas
sorbitol
dehydrogenas
remain
unchang
h
mice
given
fi
nal
dose
snalp
contain
zebov
sirna
even
highest
cumul
dose
fi
gure
complet
blood
cell
diff
erenti
count
also
unaff
ect
dose
test
mice
fi
gure
three
macaqu
given
four
treatment
snalp
contain
pool
sirna
control
develop
clinic
symptom
consist
zebovinduc
haemorrhag
fever
day
tabl
control
anim
succumb
zebov
infect
blood
collect
day
fi
gure
one
treat
anim
number
develop
high
zebov
viraemia
day
tabl
succumb
day
fi
gure
zebov
detect
plasma
one
remain
treat
anim
number
day
unabl
detect
zebov
plasma
tabl
anim
surviv
seven
dose
snalp
contain
pool
sirna
eff
ectiv
clinic
symptom
zebov
infect
treat
macaqu
less
sever
given
four
dose
tabl
control
anim
inject
snalp
contain
luc
mod
succumb
haemorrhag
fever
day
wherea
four
anim
given
pool
antizebov
sirna
surviv
fi
gure
zebov
detect
plasma
second
control
anim
day
tabl
low
level
zebov
detect
day
plasma
four
macaqu
inject
snalp
contain
zebov
sirna
day
one
anim
anim
wherea
unabl
detect
zebov
anim
day
tabl
peak
viraemia
surviv
sirnatr
macaqu
never
exceed
log
pfuml
tabl
clinic
assess
also
show
aggress
snalp
treatment
regimen
well
toler
macaqu
minor
chang
liver
enzym
alanin
aminotransferas
increas
aspart
aminotransferas
increas
possibl
relat
viral
infect
six
anim
surviv
zebov
challeng
two
studi
healthi
day
euthanis
day
seven
treatment
antizebov
sirna
inhibit
replic
viru
complet
protect
rhesu
monkey
death
haemorrhag
fever
previou
studi
zebovinfect
rhesu
monkey
succumb
viraemia
day
exposur
greater
log
pfuml
wherea
anim
treat
therapeut
surviv
viraemia
reach
level
geisbert
tw
unpublish
current
studi
viraemia
never
exceed
log
pfuml
surviv
anim
develop
treatment
ebovinduc
haemorrhag
fever
slow
previou
candid
treatment
shown
complet
protect
zebov
haemorrhag
fever
nonhuman
primat
success
achiev
intervent
mitig
coagul
disord
characteris
ebov
infect
protect
nonhuman
primat
zebov
administ
liveattenu
recombin
vesicular
stomat
viru
vaccin
vector
express
zebov
glycoprotein
shortli
lethal
zebov
challeng
sever
new
postexposur
treatment
base
sirna
antisens
oligom
shown
promis
result
rodent
model
report
assess
either
treatment
strategi
ebov
challeng
nonhuman
primat
faith
reproduc
human
ebov
infect
anim
model
model
rapid
uniformli
lethal
death
naiv
rhesu
macaqu
challeng
zebov
seed
stock
dose
rout
present
studi
geisbert
tw
unpublish
anim
typic
succumb
day
challeng
viru
mean
time
death
day
zebov
target
sirna
postexposur
treatment
studi
guineapig
l
polymeras
gene
treatment
initi
h
zebov
challeng
complet
fever
defi
ned
temperatur
greater
baselin
temperatur
least
greater
baselin
temperatur
least
mild
rash
defi
ned
focal
petechia
cover
less
skin
moder
rash
defi
ned
petechia
cover
skin
sever
rash
defi
ned
petechia
ecchymos
cover
skin
lymphopenia
defi
ned
least
reduct
number
lymphocyt
thrombocytopenia
defi
ned
least
reduct
number
platelet
astaspart
aminotransferas
alpalkalin
phosphatas
altalanin
aminotransferas
glutamyltransferas
bunblood
urea
nitrogen
given
sirna
seven
treatment
nonspecifi
c
sirna
protect
anim
target
complet
protect
mice
zebov
challeng
antisens
oligom
administ
h
zebov
exposur
target
combin
l
polymeras
gene
also
complet
protect
mice
incomplet
protect
guineapig
given
h
zebov
challeng
although
rnainterferencemedi
treatment
strategi
show
potenti
combat
ebov
infect
system
administr
synthet
manufactur
sirna
duplex
activ
innat
immun
respons
induc
high
level
infl
ammatori
cytokin
tumour
necrosi
factor
interleukin
interferon
particularli
interferon
might
contribut
antivir
activ
vivo
target
eff
ect
toxic
host
also
confound
interpret
preclin
data
sirna
must
therefor
modifi
ed
prevent
detriment
immun
activ
vivo
particularli
immuno
stimul
human
be
much
toxic
rodent
therefor
test
immun
stimulatori
activ
snalp
contain
antizebov
sirna
mice
human
pbmc
cultur
zebov
cocktail
immun
stimulatori
limit
sensit
assay
use
data
pcr
data
suggest
antivir
eff
ect
nonhuman
primat
result
specifi
c
rna
interfer
reticuloendotheli
cell
due
immun
stimul
target
eff
ect
addit
death
macaqu
given
control
luc
mod
day
within
normal
rang
expect
time
death
histor
untreat
control
also
suggest
zebovmedi
protect
specifi
c
sirna
relat
target
eff
ect
immun
toxic
associ
sirna
compon
snalp
abrog
use
select
chemic
modifi
cation
major
remain
toxic
mous
nonhuman
primat
model
hepatotox
associ
snalp
lipid
compon
maclachlan
unpublish
preliminari
toler
studi
mice
show
seven
daili
dose
mgkg
mgkg
cumul
snalp
contain
zebov
sirna
well
toler
corrobor
lack
hepatotox
measur
increas
liver
enzym
alanin
aminotransferas
aspart
aminotransferas
treat
macaqu
surviv
infect
investig
design
proofofconcept
studi
rhesu
macaqu
model
use
repres
worsecas
scenario
accident
needl
stick
exposur
laboratori
worker
fi
rst
respond
high
infecti
dose
zebov
occur
sever
time
past
year
zebov
infect
human
be
normal
progress
slower
macaqu
case
fatal
rate
man
rang
suggest
therapeut
window
could
larger
experiment
infect
macaqu
nonetheless
focu
futur
studi
need
investig
whether
antizebov
sirna
benefi
cial
administ
onset
symptom
show
substanti
progress
treatment
zebov
infect
nonhuman
primat
compar
previous
describ
postexposur
method
aff
ord
partial
protect
nonhuman
primat
zebov
progress
licens
studi
done
guineapig
nonhuman
primat
model
zebov
infect
accord
us
food
drug
administr
guidelin
assess
treatment
center
diseas
control
prevent
categori
threat
number
addit
studi
need
done
obtain
data
pharmacolog
dose
toxicolog
uninfect
nonhuman
primat
contributor
twg
achl
mr
aj
leh
im
conceiv
design
experi
twg
wrote
research
programm
plan
anim
protocol
studi
leh
wrote
modifi
cation
anim
protocol
twg
leh
select
zebov
l
polymeras
target
twg
achl
vs
mr
aj
leh
im
select
zebov
target
twg
codesign
l
polymeras
sirna
achl
vs
codesign
sirna
achl
vs
aj
design
modifi
cation
sirna
vs
anh
vitro
sirna
assay
jbg
jcj
ebola
challeng
experi
nonhuman
primat
clinic
patholog
assay
jbg
ebola
viru
infect
assay
sdj
immunolog
uptak
assay
mr
assay
twg
achl
mr
jbg
anh
jcj
aj
leh
im
analys
data
twg
mr
cowrot
report
leh
im
edit
report
author
seen
approv
fi
nal
version
report
